Trade

with

Amgen Inc
(NASDAQ: AMGN)
AdChoices
147.26
+0.01
+0.01%
After Hours :
147.26
0.00
0.00%

Open

146.99

Previous Close

147.25

Volume (Avg)

5.32M (3.71M)

Day's Range

145.52-147.50

52Wk Range

108.20-148.14

Market Cap.

111.86B

Dividend Rate (Yield )

2.44 (1.56%)

Beta

0.54

Shares Outstanding

759.61M

P/E Ratio (EPS)

22.57 (6.53)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 18.68B

    • Net Income

    • 5.08B

    • Market Cap.

    • 111.86B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 25.74

    • PEG (Price/Earnings Growth) Ratio

    • 1.55

    • Beta

    • 0.54

    • Forward P/E

    • 16.45

    • Price/Sales

    • 5.80

    • Price/Book Value

    • 4.59

    • Price/Cash flow

    • 14.62

      • EBITDA

      • 7.15B

      • Return on Capital %

      • 8.20

      • Return on Equity %

      • 22.27

      • Return on Assets %

      • 8.20

      • Book Value/Share

      • 32.10

      • Shares Outstanding

      • 759.61M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.61 (11/10/2014)

      • Dividend Declaration Date

      • 10/17/2014

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 147.00

        • Credit Rating

        • A

        • Analysts

        • 7

        • EPS Estimate

        • 7.61

        • Cashflow Estimate

        • 10.25

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 10.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 16.90

          • 17.04

          • Net Income

            Q/Q (last year)

          • 23.00

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 4.48

          • 63.43

          • Net Income

            5-Year Annual Average

          • 3.90

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 79.51

            • 82.75

            • Pre-Tax Margin

            • 28.16

            • 39.38

            • Net Profit Margin

            • 25.74

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 84.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 30.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 27.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.26

              • 0.76

              • Current Ratio

              • 4.36

              • 2.92

              • Quick Ratio

              • 3.67

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 2.85

              • 2.21

              • Book Value/Share

              • 32.10

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 20.49

                • 217.39

                • P/E Ratio 5-Year High

                • 22.12

                • 634.30

                • P/E Ratio 5-Year Low

                • 7.30

                • 124.82

                • Price/Sales Ratio

                • 5.27

                • 9.52

                • Price/Book Value

                • 4.16

                • 8.61

                • Price/Cash Flow Ratio

                • 14.62

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 22.27

                    (21.20)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 8.20

                    (9.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 9.80

                    (10.10)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 250.45k

                  • 117.08k

                  • Inventory Turnover

                  • 1.39

                  • 1.48

                  • Asset Turnover

                  • 0.32

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  5.87B
                  Operating Margin
                  31.41
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  14.62
                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Large Growth

                  Amgen Inc is a Delaware corporation was incorporated in 1980. The Company is a biotechnology medicines company. It discovers, develops, manufactures and delivers human therapeutics. Its medicines help patients fight against cancer, k...moreidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. The Company operates in one business segment which includes human therapeutics. Its products are Neulasta®, NEUPOGEN®, ENBREL, Aranesp®, EPOGEN®, XGEVA®, Prolia® and Sensipar®/Mimpara®. The products it manufactures include both biologics and small molecule drugs. The majority of its products are biologics which are produced in living systems and are inherently complex due to naturally-occurring molecular variations. In addition to its marketed products, it has various product candidates ...morein mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company competes with other clinical trials for eligible patients, which may limit the number of available patients who meet the criteria for certain clinical trials.lessless

                  Key People

                  Mr. Robert A. Bradway

                  CEO/Chairman of the Board/Director/President

                  David W. Meline

                  Executive VP/CFO

                  Brian Mcnamee

                  Executive VP, Divisional

                  Anthony C. Hooper

                  Executive VP, Divisional

                  Madhu Balachandran

                  Executive VP, Divisional

                  • Amgen Inc

                  • One Amgen Center Drive

                  • Thousand Oaks, CA 91320-1799

                  • USA.Map

                  • Phone: +1 805 447-1000

                  • Fax: +1 805 447-1010

                  • amgen.com

                  Incorporated

                  1980

                  Employees

                  20,000